The rapid growth in the GLP-1 medication market got yet another boost this week as Health Canada approved Eli Lilly’s once-a-day oral pill Foundayo for weight loss.
Eli Lilly has already cemented its position as market leader, with sales of its drugs Zepbound and Mounjaro skyrocketing.
As Foundayo is on the horizon for Canadians, how does the pill compare to injectable GLP-1 drugs?
On Wednesday, Eli Lilly’s Foundayo was approved for adults with obesity as well as those who are overweight and have at least one related medical problem, such as high blood pressure or sleep apnea.
In addition to promoting and maintaining weight loss, the pill is…
Read the full article at GLOBALNEWS.CA



